Author

R. Asby

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. J. P. Huntly· 2 shared G. Giotopoulos· 2 shared N. Sakakini· 2 shared P. Madrigal· 2 shared S. E. Richardson· 2 shared S. J. Horton· 2 shared A. Garcia-Gimenez· 1 shared A. S. M. Magee· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. J. P. Huntly

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mutational synergy with CREBBP loss in lymphomagenesis identified through forward insertional mutagenesis in a new DLBCL mouse model

N. Sakakini, R. Straver, D. Azazi, S. J. Horton, R. Asby, S. E. Richardson, P. Madrigal, E. E. Soilleux, R. J. M. Bashford-Rogers, J. de Ridder, B. J. P. Huntly

bioRxiv · Mar 25, 2024 · PreprintCancer Biology

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

A. Garcia-Gimenez, J. E. Ditcham, D. M. A. Azazi, E. Meduri, R. Asby, N. Sakakini, C. K. Lopez, N. Narayan, T. Beinortas, J. Bagri, S. Agrawal Singh, G. Giotopoulos, M. P. Murphy, S. J. Horton, B. Huntly, S. E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death.

K. Woodley, L. S. Dillingh, G. Giotopoulos, P. Madrigal, K. M. Rattigan, C. Philippe, V. Dembitz, A. S. M. Magee, R. Asby, L. N. van de Lagemaat, C. Mappereley, S. C. James, J. H. Prehn, K. Tzelepis, K. Rouault-Pierre, , P. Gallipoli

This study shows that inhibiting mannose metabolism sensitizes AML cells to cytarabine and FLT3 inhibitors by promoting ferroptotic cell death through fatty acid metabolism changes.

bioRxiv · May 16, 2022Cancer Biology